Grifols, S.A. stock is up 15.11% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 7 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT. 0% of analysts rate it a buy.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Company offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.